Pluristem Therapeutics’ CEO Issues Shareholder Letter
- Form
- 8-K
- Filed
- Period
- Importance
- Major
- Accession
- 0001213900-19-011923
- Document
- 8-K
- Exhibit 99.1
- Press release dated July 2, 2019
- Reports an executive or board change (5.02)
- Discloses other events (8.01)
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- ProPhase Labs PRPH public float $15M, Jun 30, 2025
- Akari Therapeutics AKTX public float $15M, Jun 30, 2025
- X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
- CalciMedica CALC public float $16M, Jun 30, 2025
- Lipocine LPCN public float $16M, Jun 30, 2025
